1. Protein Tyrosine Kinase/RTK
  2. c-Met/HGFR
  3. Dalmelitinib

Dalmelitinib 

Cat. No.: HY-147259
Handling Instructions

Dalmelitinib is an orally active selective c-Met kinase inhibitor (IC50: 2.9 nM) that binds to the ATP-binding region of c-Met. Dalmelitinib induces the phosphorylation of MET, partially or completely inhibits the phosphorylation of AKT and ERK. Dalmelitinib potently inhibits cancer cell (c-Met oncogene amplification) proliferation, and is used for the research of cancers like human non-small cell lung cancer (NSCLC).

For research use only. We do not sell to patients.

Dalmelitinib Chemical Structure

Dalmelitinib Chemical Structure

CAS No. : 1637658-98-0

Size Stock
100 mg   Get quote  
250 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Dalmelitinib is an orally active selective c-Met kinase inhibitor (IC50: 2.9 nM) that binds to the ATP-binding region of c-Met. Dalmelitinib induces the phosphorylation of MET, partially or completely inhibits the phosphorylation of AKT and ERK. Dalmelitinib potently inhibits cancer cell (c-Met oncogene amplification) proliferation, and is used for the research of cancers like human non-small cell lung cancer (NSCLC)[1].

In Vitro

Dalmelitinib (Compound 4 d) binds to the ATP-binding region of c-Met kinase, and shows slective inhibitory activity against c-Met with an IC50 value of 2.9 nM[1].
Dalmelitinib (0-1 μM approximately, 3 days) inhibits cell proliferation in various c-Met oncogene amplification cancer cell lines, with IC50 values ranging from 6 nM to 33 nM[1].
Dalmelitinib (0.1-1 μM, 6-24 h) significantly induces the phosphorylation of the tyrosine kinases (MET), partially or completely inhibits the downstream phosphorylation of ERK and AKT in HCCLM3 cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: C-Met oncogene amplification cancer cell: SNU-5, HCCLM3, MHCC97-H, MHCC97-L, MKN-45, NCI-H1993.
No C-Met oncogene amplification cancer cell: Huh-7, NCI-N87, NCI-1975, A549.
Concentration: 0-1 μM approximately.
Incubation Time: 3 days
Result: IC50: 33 nM (HCCLM3), 6 nM (MHCC97-H, MKN-45), 7 nM (MHCC97-L), 14 nM (NCI-H1993), 2 nM (SNU-5); Other cells: > 1000 nM.

Western Blot Analysis[1]

Cell Line: C-Met oncogene amplification cancer cell: SNU-5, HCCLM3, MHCC97-H, MHCC97-L, MKN-45, NCI-H1993.
No C-Met oncogene amplification cancer cell: Huh-7, NCI-N87, NCI-1975, A549.
Concentration: 0.1, 0.3, 1 μM
Incubation Time: 6-24 h
Result: Significantly induced the phosphorylation of the tyrosine kinases (MET), partially inhibited the downstream phosphorylation of AKT, and completely inhibited the downstream phosphorylation of ERK.
In Vivo

Dalmelitinib (Compound 4 d, intragastric administration, 10-60 mg/kg) significantly inhibits the tumor growth in a dose-dependent manner in MKN-45 tumor xenograft nude mice[1].
Dalmelitinib (intragastric administration, 5 mg/kg for a single dose) shows a high plasma concentration, longer half-life and mean residence time, low clearance rates in BALB/c small nude mice[1].
Dalmelitinib shows a high level of No Observed Adverse Effect Level (NOAEL) in mice long-term toxicity (225 mg/kg/day) and acute toxicity (600 mg/kg/day)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: MKN-45 tumor xenograft nude mice[1]
Dosage: 10, 30, 60 mg/kg
Administration: Intragastric administration
Result: Inhibited the tumor growth with the inhibitory rates of 29.5% (10 mg/kg), 34.2% (30 mg/kg), and 61.4% (60 mg/kg).
Animal Model: BALB/c small nude mice (pharmacokinetic assay)[1]
Dosage: 5 mg/kg for a single dose
Administration: Intragastric administration
Result: Pharmacokinetic profile of Dalmelitinib (Compound 4 d)
Compound Cmax (ng/mL) AUC (ng/mL/h) t1/2 (h) MRT (h) CL/F (mL/min/kg) Vz/F
Dalmelitinib 8628 122487 5.55 9.10 0.68 327
Molecular Weight

461.47

Formula

C22H16FN7O2S

CAS No.
SMILES

O=C1N(C)C2=CN=C3C=CC(SC4=NN=C5C(F)=CC(C6=CN(C)N=C6)=CN45)=CC3=C2OC1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Dalmelitinib
Cat. No.:
HY-147259
Quantity:
MCE Japan Authorized Agent: